WO2008152223A1 - Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 - Google Patents
Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 Download PDFInfo
- Publication number
- WO2008152223A1 WO2008152223A1 PCT/FR2008/000620 FR2008000620W WO2008152223A1 WO 2008152223 A1 WO2008152223 A1 WO 2008152223A1 FR 2008000620 W FR2008000620 W FR 2008000620W WO 2008152223 A1 WO2008152223 A1 WO 2008152223A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- ethyl
- methyl
- dipyrrolidin
- ylpyrimidin
- Prior art date
Links
- 0 CC*(C)N(*)C(C)(C)CC(C)(C)C Chemical compound CC*(C)N(*)C(C)(C)CC(C)(C)C 0.000 description 5
- FBAOOCXFUXICRT-UHFFFAOYSA-N NC(CC1)CCN1c1nccc(C(F)(F)F)n1 Chemical compound NC(CC1)CCN1c1nccc(C(F)(F)F)n1 FBAOOCXFUXICRT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to novel triamino pyrimidine derivatives. These products have a Cdc25 phosphatase inhibitory activity.
- the invention also relates to a process for the synthesis of these compounds as well as therapeutic compositions containing them and their use as a medicament.
- kinases The control of the transition between the different phases of the cell cycle during mitosis or meiosis is provided by a set of proteins whose enzymatic activities are associated with different states of phosphorylation. These states are controlled by two major classes of enzymes: kinases and phosphatases.
- CDKs cyclin-dependent kinases
- the enzymatic activity of these different CDKs is controlled by two other families of enzymes that work in opposition (Jessus and Ozon, Prog, CeIl Cycle Res. (1995), 1, 215-228).
- the first group includes kinases such as Weel and Mikl which deactivate CDKs by phosphorylating certain amino acids (Den Haese et al., Mol Biol, CeIl (1995), 6, 371-385).
- the second group includes phosphatases such as Cdc25 which activate CDKs by dephosphorylating tyrosine and threonine residues of CDKs (Gould et al., Science (1990), 250, 1573-1576).
- Phosphatases are classified into 3 groups: serine / threonine phosphatases (PPases), tyrosine phosphatases (PTPases) and dual specificity phosphatases (DSPases). These phosphatases play an important role in the regulation of many cellular functions.
- Cdc25-A, Cdc25-B and Cdc25-C encode Cdc25 proteins.
- variants derived from alternative splicing of the Cdc25B gene have been identified: they are Cdc25B1, Cdc25B2 and Cdc25B3 (Baldin et al., Onc ⁇ gene (1997), 14, 2485-2495).
- Cdc25 phosphatases The role of Cdc25 phosphatases in oncogenesis is now better known and the mechanisms of action of these phosphatases are illustrated in particular in the following references: Gal forceov et al., Science (1995), 269, 1575-1577; Gal forceov et al., Nature (1996), 382, 511-517; and Mailand et al., Science (2000), 288, 1425-1429.
- Cdc25 phosphatases also play a role in neurodegenerative diseases (see Zhou et al., Mol. Life ScL (1999), 56 (9-10), 788-806, Ding et al., Am. 2000), 157 (6), 1983-90, Vincent et al., Neuroscience (2001),
- Another problem addressed by the invention is the search for drugs intended to prevent or treat rejection of organ transplants or to treat autoimmune diseases. In these disorders and / or diseases, inappropriate activation of lymphocytes and monocytes / macrophages is involved.
- the immunosuppressive drugs known to date have side effects that could be decreased or modified by products specifically targeting signaling pathways in hematopoietic cells that initiate and maintain inflammation
- the tannin-pyimidine deficits as defined below are new inhibitors of Cdc25 phosphatases. They are likely to be used as drugs, particularly in the treatment and / or prevention of the following diseases or disorders:
- angiogenesis e.g. angiogenesis, psoriasis or estenosis
- tumoural pyelotic diseases e.g. a tumoral pyelotic diseases
- paiasitan diseases piotozoal infection
- the compounds of the present invention are also, because of their inhibitory properties of Cclc25 phosphatases, which may be used to inhibit or inhibit prevent the proliferation of microorganisms, especially yeasts.
- One of the advantages of these compounds is their low toxicity on healthy cells.
- the present invention relates to a compound of general formula (I)
- R2 represents a hydrogen atom or a linear or branched C 1 to C 1 alkyl radical
- W represents -NR6-, -CR6R7-, an oxygen atom or a sulfur atom
- R6 and R7 independently represent a hydrogen atom or an alkyl radical
- n or q are integers between 2 and 6 inclusive;
- R3 represents a hydrogen atom or an alkyl radical
- R4 and R5 independently represent a hydrogen atom, an alkyl radical, an aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radical; or R4 and R5 together with the nitrogen atom to which they are attached form a heterocycloalkyl;
- R8 represents a hydrogen atom or one of the following radicals: o alkyl,
- heteroaryl optionally substituted with one or more identical or different groups chosen from: alkyl, heterocycloalkyl, halo and aryloxy optionally substituted by one or more identical or different halogens,
- aryl optionally substituted with one or more identical or different groups chosen from: alkyl; alkoxy; alkylthio; dialkylamino; halo; haloalkyl; haloalkyloxy; cyano; nitro; heteroaryl; heteroarylthio optionally substituted with one or more identical or different groups selected from halo, haloalkyl; aryloxy optionally substituted with one or more nitro groups; arylsulfonyl optionally substituted with one or more identical or different halogens; or a radical -SO 2 NRI5RI6;
- an arylalkyl radical optionally substituted with one or more identical or different halogens, or;
- R9 represents one of the following radicals:
- aryl optionally substituted by one or more arylcarbonyl radicals
- heteroaryl optionally substituted with a heteroaryl itself optionally substituted by a haloalkyl group
- RIO represents an aryl radical optionally substituted with one or more identical or different groups chosen from haloalkyl, nitro;
- R15 and R16 independently represent a heteroaryl radical optionally substituted by one or more alkyl to C 3 identical or different, alkyl to C 3, an aryl radical or a hydrogen atom; or R15 and R16 may together form a heterocycloalkyl including the nitrogen atom;
- alkyl When alkyl is not given more precisely, it is meant a linear or branched alkyl radical containing from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, or hexyl.
- alkylamino or dialkylamino is understood to mean an amino radical substituted with one or two alkyl radicals as previously defended, such as, for example, methylamino, dimethylamino, methylethylamino, ethylamino or diethylamino.
- aminoalkyl alkylaminoalkyl or dialkylaminoalkyl is meant an alkyl radical as defeni previously substituted by an amino radical, or an alkylamino radical or dialkylamino as defined above such as dimethylaminoethyl or diethylaminoethyl.
- alkoxy means an -O-alkyl radical in which the alkyl radical is as previously defined, for example the methoxy or ethoxy radical.
- alkylthio is understood to mean an -S-alkyl radical in which the alkyl radical is as previously defined, for example the methylthio or ethylthio radical.
- haloalkyl an alkyl radical as defined above substituted with one or more identical or different halogen atoms such as, for example, trifluoromethyl or pentafluoroethyl.
- haloalkyloxy is meant a -O- (haloalkyl) radical in which the haloalkyl radical is as previously defined, such as, for example, the trifluoromethoxy radical.
- cycloalkyl when not more precise is meant a saturated carbon ring radical comprising 3 to 6 members such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and preferably cyclopentyl and cyclohexyl.
- heterocycloalkyl or heterocyl is understood to mean a ring having from 3 to 6 members and comprising one or more identical or different heteroatoms chosen from O, N and S, for example an azeridinyl, azetidinyl or pyrrolidinyl radical, piperidinyl, morpholinyl, tetrahydrofuran
- heterocycloalkylalkyl an alkyl radical substituted by a heterocycloalkyl as defined above, such as, for example, the tetrahydrofurylmethyl radical.
- aryl or aromatic carbocycle is meant an unsaturated carbocyclic system comprising at least one aromatic ring, and preferably a radical selected from phenyl, naphthyl and fluorenyl.
- aryloxy is meant an -O-aryl radical in which the aryl radical is as defined above, such as, for example, the phenoxy radical.
- arylalkyl is meant an alkyl radical as defined above substituted with an aryl radical as defined above, such as, for example, the benzyl radical or the phenethyl radical.
- arylcarbonyl is meant an aryl-substituted carbonyl group as defined above, such as, for example, the phenylcarbonyl radical.
- aryloxyalkyl is understood to mean an alkyl radical substituted with aryloxy as defined above, for example phenoxymethyl or phenoxyethyl.
- arylsulfonyl means an -SO 2 -aryl radical in which the aryl radical is as defined above, such as, for example, the phenylsulfonyl radical.
- heteroaryl within the meaning of the present invention is meant an aromatic unsaturated ring comprising one or more identical or different heteroatoms chosen from N, O and S such as furyl, thienyl isoxazolyl, benzothiadiazolyl, pyridinyl, oxazolyl, pyrazolyl, pyrimidinyl or quinoxalyl.
- heteroarylalkyl an alkyl radical substituted with a heteroaryl as defined above, such as for example the furylmethyl radical.
- heteroarylthio is understood to mean an -S-heteroaryl radical in which the heteroaryl radical is as previously defined, for example the pyridylthio radical.
- salt of a compound is meant the addition salts of said compound with an organic or inorganic acid or, where appropriate, with a base, and in particular the pharmaceutically acceptable salts of said compound.
- salt in particular inorganic acid addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, diphosphate and nitrate or organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate. , lactate, methanesulfonate, p-toluenesulfonate, pamoate and stearate.
- salts formed from bases such as sodium or potassium hydroxide.
- the compounds according to the present invention may comprise asymmetric carbon atoms. Therefore, the compounds of the present invention have two possible enantiomeric forms, i.e. the "R” and “S” configurations.
- the present invention includes both enantiomeric forms and any combinations of these forms, including racemic "RS" mixtures.
- RS racemic
- the subject of the invention is also a compound of general formula (I), characterized in that R4 and R5 independently represent a hydrogen atom, an alkyl, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radical.
- the subject of the invention is also a compound of general formula (I), characterized in that R4 and R5 together with the nitrogen atom to which they are attached form a heterocycloalkyl.
- the subject of the invention is particularly a compound of general formula (I) in which
- R2 represents a hydrogen atom
- W represents -CR6R7-
- R6 and R7 independently represent a hydrogen atom or an alkyl radical
- R3 represents a hydrogen atom
- R4 and R5 together with the nitrogen atom to which they are attached form a heterocycloalkyl having only one nitrogen atom; and R8 represents an aryl radical optionally substituted with one or more identical or different groups chosen from alkyl and alkoxy; alkylthio; halo; haloalkyl; cyano; nitro; heteroarylthio optionally substituted with one or more identical or different groups selected from halo, haloalkyl; aryloxy optionally substituted with one or more nitro groups; and preferentially when the term heterocycloalkyl denotes a pyrrolidine or a piperidine; the aryl term of the aryl and aryloxy radicals is the phenyl radical; and the heteroarylthio group is the pyridinylthio group.
- the invention relates to a compound of general formula (I) wherein W represents -NR6- or an oxygen atom, and very preferably W represents -NR6- or an oxygen atom and R1 represents a radical -
- the invention particularly relates to a compound in which R2 represents a hydrogen atom, R4 and R5 together with the nitrogen atom to which they are attached a heterocycloalkyl containing only carbon atoms, nitrogen, and optionally oxygen, and preferably a heterocycloalkyl having only one nitrogen atom.
- the subject of the invention is a compound of general formula (I), characterized in that:
- R2 represents a hydrogen atom
- W represents -NR6- or the oxygen atom
- R6 represents an alkyl radical
- R3 represents a hydrogen atom
- R4 and R5 independently represent a hydrogen atom, an alkyl radical; or R4 and R5 together with the nitrogen atom to which they are attached form a heterocycloalkyl having only one nitrogen atom;
- R8 represents an aryl radical optionally substituted with one or more identical or different groups chosen from alkyl and alkoxy; alkylthio; halo; haloalkyl; cyano; nitro; heteroarylthio optionally substituted with one or more identical or different groups selected from halo, haloalkyl; aryloxy optionally substituted with one or more nitro groups; a radical -SO 2 NRISRIO;
- R15 and R16 may together form a heterocycloalkyl comprising a nitrogen atom, or R15 and R16 independently represent a heteroaryl radical optionally substituted by one or more C 1 to C3 are identical or different, an alkyl radical in C 1 -C 3 an aryl radical or a hydrogen atom; and preferentially when the term heterocycloalkyl denotes a pyrrolidine or a piperidine; the aryl term of the aryl and aryloxy radicals is the phenyl radical; and the heteroaryl term of the heteroaryl and heteroarylthio radicals is pyridine or pyrimidine.
- aryl term of the aryl, aryloxy, arylsulfonyl, arylalkyl, aryloxyalkyl and arylcarbonyl radicals preferably represents the phenyl, naphthyl or fluronenyl radical, and / or
- heteroaryl of the heteroaryl, heteroarylalkyl and heteroarylthio radicals preferably represents the furyl, thienyl isoxazolyl, benzothiadiazolyl, pyridinyl, oxazolyl, pyrazolyl, pyrimidinyl or quinoxalyl radical; and or
- cycloalkyl preferably represents cyclopentyl or cyclohexyl
- heterocycloalkyl of the heterocycloalkyl and heterocycloalkylalkyl radicals preferably represents the tetrahydrofuryl, azetidinyl, pyrrolidinyl, morpholinyl or piperidyl radical.
- the subject of the present invention is also the compounds of general formula (I)
- W is independently NR6, CR6R7, an oxygen atom or a sulfur atom with the proviso that R6 and R7 are independently hydrogen or linear alkyl or branched C l -C 6;
- R3 represents a hydrogen atom or a linear or branched C1-C4 alkyl radical
- R2 represents a hydrogen atom, a linear or branched C 1 -C 3 alkyl radical
- R4 and R5 together form a heterocycle comprising the nitrogen atom; or R4 and R5 independently represent a hydrogen atom, a linear or branched alkyl radical C l -C 6, a phenyl radical, an alkylaminoalkyl radical or a - (CH 2) 2 -N (CH 3) 2;
- n or q are integers between 2 and 6 inclusive;
- R8 represents either a hydrogen atom, a linear or branched alkyl radical C l -C 6, a thiophene radical, a naphthyl radical, a tetrahydronaphthyl, a cyclopentyl group, a benzothiadiazole group, an isoxazole group optionally substituted by 1 or 2 alkyl radicals in C 2, a methylfuryl group, a tetrahydrofuryl group, a benzyl radical optionally substituted by a halogen atom, or a pyridine group optionally substituted with a radical phen ⁇ xy, by a halogen atom, a radical halophenoxy or with a morpholino radical; or
- R8 represents a radical 2
- R 11, R 12, R 13, R 14 or R 17 independently represent a hydrogen atom, a halogen atom, a radical -CN, -NO 2 , -OCF 3 , -CF 3 , an alkylthio radical, an alkylamino radical, an oxazole radical, a pyrazole radical, an alkoxy radical, a phenoxy radical which is optionally substituted with a radical -NO 2 , a linear or branched C 1 -C 6 alkyl radical, a thiopyridine radical optionally substituted by a halogen atom and by a -CF 3 radical, an arylsulphone radical optionally substituted with a halogen atom,
- R12, R13, R14 or R17 independently represent an -SO2-NR15R16 radical, it being understood that R15 and R16 may together form a heterocycle comprising the nitrogen atom; or one of R15 or R16 independently represents a dimethylpyrimidine radical, a C 1 -C 3 alkyl radical, a phenyl radical or a hydrogen atom;
- R9 represents a radical
- IO represents a radical
- the subject of the present invention is the compounds of general formula
- W is independently NR 6 with R 6 represents a hydrogen atom or a linear or branched alkyl radical C l -C 6;
- R3 represents a hydrogen atom, a linear or branched C1-C4 alkyl radical
- R2 independently represents a hydrogen atom, a linear or branched alkyl radical C l -C 3;
- R4 and R5 together form a heterocycle comprising the nitrogen atom
- n or q are integers between 2 and 6 inclusive;
- R8 represents either a hydrogen atom, a linear or branched C 1 -C 4 alkyl radical, a thiophene radical, a methylphenoxy radical, a naphthyl radical, a dihydronaphthyl radical, a cyclopentyl radical, a benzothiadiazole radical or an optionally isoxazole radical; substituted with 1 or 2 methyl radicals, a pyrazole radical, a methylfuryl radical, a methyldihydrofuryl radical, a benzyl radical optionally substituted with a fluorine atom, or a pyridine radical optionally substituted with a phenoxy radical, with a halogen atom, with a fluorophenoxy radical or a morpholino radical;
- R8 represents a radical
- R 11, R 12, R 13, R 14 or R 17 independently represent a hydrogen atom, a halogen atom, a radical -CN, -NO 2 , -OCF 3 , -CF 3 , -S-CH 3 , a radical dimethyl amine, an oxazole radical, a methoxy radical, a phenoxy radical optionally substituted with a radical -NO 2 , a linear or branched C 1 -C 6 alkyl radical, thiopyridine optionally substituted with halogen atoms or -CF 3 , a arylsulfone radical optionally substituted by a halogen atom,
- R12, R13, R14 or R17 independently represent a radical
- R15 and R16 may together form a heterocycle comprising the nitrogen atom
- the compound according to the invention has radicals R4 and R5 which together form a heterocycle comprising the nitrogen atom, and more particularly which form a pyrrolidine radical.
- the compound according to the invention has a radical R 3 which represents a hydrogen atom.
- the compound according to the invention is such that n or q are integers equal to 2 or 3, more particularly n and q are equal to 2.
- the compound according to the invention has a radical W which represents a radical NR6, and more particularly which represents a radical NR6 with R6 being a linear alkyl radical.
- R 11, R 12, R 13, R 14 or R 17 independently represent a hydrogen atom, a halogen atom, a radical -CN, -NO 2 , -CF 3, an alkoxy radical or a phenoxy radical.
- the invention more particularly relates also to a compound of general formula (I) characterized in that it is selected from •
- the compounds according to the invention may be prepared according to the reaction schemes described below.
- the di-aminopyrimidine derivatives of general formula (IV) can be prepared according to the method described by Bundy et al. In Journal of Medicinal Chemistry, 1995, 35, 4161-4163 by reacting, for example, the compound (II) in which z, z and z "represent a halogen atom and preferably a chlorine atom, with the amino compound of general formula (III) wherein R4 and R5 are as previously defined, at a temperature of between -5 ° C. and 5 ° C. (preferably 0 ° C.), in an inert solvent such as, for example, tetrahydrofuran.
- an inert solvent such as, for example, tetrahydrofuran.
- R4 and R5 both represent a methyl radical and in the particular case where R4 and R5 represent a hydrogen atom and an ethyl radical
- the conditions of preparation of the derivatives of formula (IV) are as described by Atri et al. in Journal of Medicinal Chemistry, 1984, 27, 1621-1629.
- the reaction is carried out at a temperature of between 30 ° C. and 50 ° C. (preferably 40 ° C.) in a polar and inert solvent such as, for example, ethanol.
- the compounds of general formula (Ia) in which R 2, R 3, R 4, R 5, W, n and q are as defined above and R 1 represents a hydrogen atom or an alkyl radical can be obtained, for example, by heating at a temperature of between 150 ° C. and 250 ° C. (preferably 190 ° C.) or by treatment with microwaves, the compound of formula (IV) in which z "represents a halogen atom and preferably a chlorine atom, with a large excess of the diamine compound (V).
- R2, R3, R4, R5, W, n and q are as defined above and R1 is hydrogen, and obtained as described above, are used as starting material in the reaction schemes below.
- the derivatives of general formula (Ib) in which R 2, R 3, R 4, R 5, W, n, q, and R 8 are as defined above and Y represents a sulfur or oxygen atom may be prepared according to the method described in Scheme C by reacting the compound (Ia) with the isocyanate or isothiocyanate compound of the general formula (VII) at a temperature of between 10 ° C. and 30 ° C. (preferably 20 ° C.) in a polar and inert solvent such as for example, dichloromethane, 1,2-dichloromethane or dimethylformamide.
- a polar and inert solvent such as for example, dichloromethane, 1,2-dichloromethane or dimethylformamide.
- the compounds of general formula (Id) in which R2, R3, R4, R5, W, n, q, Y, and R8 are as defined above can be obtained by heating at reflux of a polar solvent such as tetrahydrofuran, the ammopyrimidine derivative of general formula (Ia) with the cyanoethylenic derivative in its salified foime of general formula (IX).
- the salified derivative of foimule (IX) can be obtained by reacting the isothiocyanate derivative of general formula (VII ') and the sodium cyanamide compound in a polar solvent, for example ethanol, at a temperature of between 10 ° C. and 10 ° C. 30 0 C (preferably 20 0 C).
- the compounds of general formula (Ie) in which R2, R3, R4, R5, W, n, q, Y, and R9 are as defined above can be obtained for example, by condensing on the acyl halide compound of general formula (X) wherein z 'represents a halogen atom and preferably a chlorine atom, the compound of formula (Ia) in the presence of a mineral acid trap as a tertiary amine compound such as triethylamine or diisopropylethylamine at a temperature between 10 0 C and 30 0 C (preferably 20 ° C) in an inert solvent such as for example, dichloromethane or ethyl ether according to methods known to those skilled in the art.
- a mineral acid trap as a tertiary amine compound such as triethylamine or diisopropylethylamine at a temperature between 10 0 C and 30 0 C (preferably 20 ° C) in an inert
- the derivatives of general formula (If) in which R2, R3, R4, R5, W, n, q, and R10 are as defined above, can be prepared according to the method described in scheme H above by reacting the compound (Ia) with the arylsulfonyl halide compound of formula (XII) in which z 'represents a halogen atom and preferably a chlorine atom, in the presence of a mineral acid scavenger such as a tertiary amine compound such as for example, triethylamine or diisopropylethylamine, in a polar solvent such as, for example, dichloromethane, 1,2-dichloromethane or dimethylformamide at a temperature of between 10 ° C. and 30 ° C. (preferably 20 ° C.) .
- a mineral acid scavenger such as a tertiary amine compound such as for example, triethylamine or diisopropylethylamine
- the invention also relates to a process for preparing a compound of general formula (I) as defined above, comprising the following steps:
- an isocyanate or isothiocyanate compound of the general formula R8NCY in which Y represents a sulfur or oxygen atom and R8 is as defined above, at a temperature of between 10 ° C. and 30 ° C. in a chosen solvent from dichloromethane, 1,2-dichloromethane or dimethylformamide to give the compound of general formula (I) wherein R1 represents -C ( ⁇ Y) -NHR8 (compound Ib);
- (Ic) is a cyanoethylenic derivative in its salified form of general formula (IX), wherein R8 is as defined above,
- (Ie) is an arylsulfonyl halide compound of fo ⁇ nule RlOSO 2 Z ', wherein z' represents a halogen atom and RIO is as defined above, in the presence of a tertiary amine in a solvent selected from the group consisting of dichloromethane, 1,2-dichloromethane or dimethylformamide at a temperature of between 10 ° C. and 30 ° C. to give the compound of general formula (I) in which R 1 represents -SO 2 -R 10 (compound If)
- the subject of the invention is also a process for preparing compounds of general formula (Ia) in which R2, R3, R4, R5, W, n and q are as defined above, and which can be obtained, for example, by heating at high temperature by microwave heating, the compound of formula (IV) with a large excess of the diamine compound (V) wherein R1 is hydrogen to form the pyrimidine monoamine derivative of general formula (Ia).
- the invention also relates to an industrial compound chosen from: 2,4-diazetid-1-yl-6-chloropyrimidine; 6-chloro-N, N'-bis [2- (dimethylamino) ethyl] -N, N'-dimethylpyriridine-2,4-diamine.
- the compounds of general formula (I) according to the present invention possess interesting pharmacological properties: they have a Cdc25 phosphatase inhibitory activity. They can therefore be used in different therapeutic applications.
- the subject of the present invention is also a pharmaceutical composition
- a pharmaceutical composition comprising, as active principle, a compound of general formula (I) as defined above, or a pharmaceutically acceptable salt of such a compound, with at least one pharmaceutically acceptable excipient. acceptable.
- the subject of the present invention is also, as a medicament, a compound of general formula (I) as defined above, or a pharmaceutically acceptable salt of such a compound.
- the present invention also relates to the use of a compound of general formula (I) as defined above or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating or preventing a disease or a disorder chosen from the following diseases or the following disorders: cancers, proliferative tumoral diseases, non-tumoral proliferative diseases, neurodegenerative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia, autoimmune diseases, rejection of transplants, inflammatory diseases or allergies.
- a disease or a disorder chosen from the following diseases or the following disorders: cancers, proliferative tumoral diseases, non-tumoral proliferative diseases, neurodegenerative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia, autoimmune diseases, rejection of transplants, inflammatory diseases or allergies.
- the present invention relates to the use of a compound of general formula (I) as defined above or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating or preventing cancers. .
- the present invention relates to the use of a compound of general formula (I) as defined above or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating or preventing the cancer, said cancer being selected from cancers of the colon, rectum, stomach, lungs, pancreas, kidney, testes, breast, the uterus, ovary, prostate, skin, bones, spinal cord, neck, tongue, head as well as sarcomas, caicinomas, fibroadenomas, neuroblastomas, leukemias, melanomas.
- the compound of general formula (I) or its salt used according to the invention may be in the form of a solid, for example powders, granules, tablets, capsules, liposomes or suppositories.
- Suitable solid supports may be for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and the like. wax.
- the compound of general formula (I) or its salt used according to the invention or the combination according to the invention may also be in liquid form, for example solutions, emulsions, suspensions or syrups.
- Appropriate liquid carriers may be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.
- the administration of a compound of general formula (I) or its salt used according to the invention or the combination according to the invention may be carried out topically, orally, parenterally, by intramuscular injection, subcutaneously, etc.
- the dose of a product according to the present invention varies according to the mode of administration, the age and the body weight of the subject to be treated as well as the state of the latter, and it will ultimately be decided by the attending physician or veterinarian.
- a quantity determined by the attending physician or veterinarian is here called a "therapeutically effective amount”.
- the envisaged administration dose for a drug according to the invention is between 0.1 mg and 10 g depending on the type of active compound used.
- the NMR analyzes of Examples 1 to 90 were carried out on a 400 MHz Bruker-Avance II spectrometer.
- the compounds are characterized by their molecular peak (MH +) determined by mass spectrometry (MS), a simple quadrupole mass spectrometer (Micromass, Platfoim model) equipped with an electiospiay source is used with a resolution of 0.8 da at 50% of valley.
- MS mass spectrometry
- a simple quadrupole mass spectrometer Micromass, Platfoim model equipped with an electiospiay source is used with a resolution of 0.8 da at 50% of valley.
- the elution conditions corresponding to the results indicated are as follows: elution with acetonitrile-water-trifluoroacetic acid 50-950-0.2 (A) for 1 minute and then passing the mixture (A) to an acetonitrile-water mixture 950-50 (B) by a linear gradient over a period of 7.5 minutes, then eluting with pure B mixture for 2 minutes.
- the compounds according to the invention can be prepared according to the various procedures described above.
- the compound 4-chloro-2,6-dipyrrolidone is heated at 190 ° C. in a microwave oven (Biotage, Emrys Optimiser) for 3600 seconds.
- Ylpyrimidine as prepared in paragraph (1-1) (0.8 g, 3.2 mmol) and N-methyl ethylenediamine (3.3 ml, 26 mmol).
- 20 ml of water are added and the mixture is extracted with ethyl acetate. Wash with 3x20 ml of water and then dry the organic phase over sodium sulfate. Evaporated to dryness and then added about 10 ml of heptane to the oil obtained. Stirred and then filtered on frit the solid obtained. A solid is obtained in the form of a white powder. The yield of the reaction is 69%.
- Example 3 N- (2,6-dipyrrolidin-l-ylpyrimidin-4-yl) - ⁇ ir, r ⁇ '-dimethyl-N' - [3- (methylammo) propyl] propane-l, 3-diamine This compound is synthesized according to the method presented for Example 1 from the compound synthesized in paragraph 1-1).
- Example 7a N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ methyl ) amino] ethyl ⁇ urea hydrochloride
- N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyl-1-propyl-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino ] ethyl ⁇ urea (0.3 g, 0.54 mmol) as prepared in Example 7 is dissolved in 10 ml of methanol. At 23 ° C., a solution of 1M hydrochloric acid in ether (3.25 ml, 3.2 mmol) is added to this solution, followed by stirring for 2 hours at this temperature. The excess hydrochloric acid is removed from the evaporator and then triturated in ether.
- Example 7b N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) ) amino] ethyl ⁇ urea sulfate
- N- [4-chloro-3- (trifluoroniethyl) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino ] ethyl ⁇ urea (0.13 g, 0.26 mmol) as prepared in Example 7 is dissolved in 1 ml of dimethylformamide. At 23 ° C., an IM sulfuric acid solution (0.13 ml, 0.13 mmol) is added to this solution and the mixture is then stirred for 30 minutes at this temperature. Add 5 ml of water and filter through the solid obtained by washing with water. After drying, a white powder is obtained.
- Example 7c N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 2- [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ methyl ) ami ⁇ o] ethyl ⁇ urea tartarate
- N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) ammo] ethyl ⁇ (methyl) amino ] ethyl ⁇ urea (0.3 g, 0.6 mmol) as prepared in Example 7 is dissolved in 3 ml of dimethylformamide. At 23 ° C., an IM tartaric acid solution (0.6 ml, 0.6 mmol) is added to this solution and then the mixture is stirred for 2 hours at this temperature. Add 7 ml of water and filter the solid obtained by washing with water. After drying, a white powder is obtained.
- Example 7d N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyridin-4-yl) amino] ethyl ⁇ (niethyl) ) ainino] ethyl ⁇ urea citrate
- N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino ] ethyl ⁇ urea (0.21 g, 0.38 mmol) as prepared in Example 7 is dissolved in 2 ml of dimethylformamide. At 23 ° C., an IM citric acid solution (0.38 ml, 0.38 mmol) is added to this solution, followed by stirring for 2 hours at this temperature. Add 5 ml of water and filter through the solid obtained by washing with water. After drying, a white powder is obtained.
- Example 11 N- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-l-ylpyrimidm-4- yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ - ⁇ r '- [(2JR) -l , 2,3,4-tetrahydronaphthalen-2-yl] urea
- Example 13 N- (3,5-dimethylisoxazol-4-yl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ urea
- Example 16 N- (4-chlorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrobidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ urea
- 1 H NMR ⁇ ppm, CDCl 3 ): 1.88-1.95 (m, 8H); 2.29 (s, 3H); 2.50-2.66 (m, 4H); 3.20- 3.52 (m, 12H); 4.72 (s, 1H); 5.17 (se, 1H); 5.72 (se, 1H); 7.14-7.31 (m, 4H); 7.87 (sé +, IH)
- Example 17 N- (3,4-dichlorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ urea
- Example 18 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -iV'-ethylurea
- Example 21a N- [4-chloro-3- (trifluoromethyl) phenyl] -N '- ⁇ 3 - [ ⁇ 3 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] propyl ⁇ (methyl) ) amino] propyl ⁇ ureahydrochloride
- Example 22 N- (4-chlorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea
- Example 22a N- (4-chlorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea hydrochloride
- the compounds 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 67, 76 and 77 were synthesized according to a method similar to that described in FIG. example 22.
- Example 26 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N'-pyridin-3-ylthiourea
- Example 27 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl] -N '- [4- (piperidin-1) -ylsulfonyl) phenyl] thiourea
- Example 28 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N'-ethylthiourea
- Example 32 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N '- (6-morpholin-4-) ylpyridin-3-yl) thiourea
- Example 33 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N '- [4- (1,3) -oxazol-5-yl) phenyl] thiourea
- Example 35 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N '- (4-methoxyphenyl) thiourea
- Example 36 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N '- (4-phenoxyphenyl) thiourea
- Example 37 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N'-1-naphthylthiourea
- Example 38 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N '- trimethoxyphenyl) thiourea
- Example 40 N- (2,4-difluorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea
- Example 43 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -N '- (4-nitrophenyl) thiourea 1 H NMR ( ⁇ ppm, DMSO): 1.84-1.94 (m, 8H); 2.31 (s, 3H); 2.65-2.70 (m, 4H); 3.22-3.74 (m, 12H); 4.70 (s, 1H); 5.35 (se, 1H); 7.50 (se, 1H); 7.82 (m, 2H); 8.12 (d, 2H); 9.50 (se, IH)
- Example 48 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl] -N '- [4- (1H-pyrazol) -l-yl) phenyl] thiourea
- Example 60 N- ⁇ 4 - [(4-bromophenyl) sulfonyl] phenyl ⁇ -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ ( methyl) amino] ethyl ⁇ thiourea
- Example 61 4 - ⁇ [( ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ amino) carbonothioyl] amino ⁇ benzenesulfonamide
- Example 62 4 - ⁇ [( ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ amino) carbonothioyl] amino ⁇ -N - phenylbenzenesulfonamide
- Example 63 N ⁇ 6 ⁇ - ⁇ 2 - [(2-aminoethyl) (methyl) amino] ethyl ⁇ -N ⁇ 2 ⁇ , N ⁇ 4 ⁇ -bis [2- (dimethylamino) ethyl] -N ⁇ 2 ⁇ , N ⁇ 4 ⁇ -dimethylpyrimidine-2,4,6-triamine
- Example 66 N- (4-chlorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dimorpholin-4-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea
- Example 69 N- (4-chlorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipiperidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea
- This compound is synthesized according to the method presented for Example 22 from the compound synthesized in paragraph 68-2)
- Example 70 N ⁇ 6 - ⁇ 2 - [(2-aminoethyl) (methyl) amino] ethyl ⁇ - N ⁇ 2 ⁇ , N ⁇ 2 ⁇ ⁇ Vf ⁇ 4 ⁇ , N ⁇ 4 ⁇ -tetraethylpyrimidine-2,4 6-triamine 70-1) 6-chloro-N, JSf, N ', N'-tetraethylpyrimidine-2,4-diamine
- Example 72 N ⁇ 6 - ⁇ 2 - [(2-aminoethyl) (methyl) amino] ethyl ⁇ - N ⁇ 2 ⁇ , N ⁇ 2 ⁇ , N ⁇ 4 ⁇ , N ⁇ 4 ⁇ -tetramethylpyrimidine-2,4 6-traminamine 72-1) 6-chloro-N, N, N ', N'-tetramethylpyriinidine-2,4-diamine
- Example 75 N- (4-chlorophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-diazetidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea
- Example 76 N- [4- (dimethylamino) phenyl] -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea 1 H NMR ( ⁇ ppm, CDCl 3 ): 1.80-1.95 (m, 8H); 2.30 (s, 3H); 2.62-2.67 (m, 4H); 2.90 (s, 6H); 3.20-3.71 (m, 12H); 4.50 (se, 1H); 4.65 (s, 1H); 6.60 (se, 1H); 6.70 (m, 2H); 7.15 (m, 2H); 7.70 (se, 1H)
- Example 77 N- (4-cyanophenyl) -N '- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimid-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ thiourea
- Example 78 N ⁇ 4 - ⁇ 2 - [(2-aminoethyl) (methyl) amino] ethyl ⁇ -N ⁇ 2 ⁇ , N ⁇ 6 ⁇ - diethylpyrimidine-2,4,6-triamine
- This compound is synthesized according to the method presented for Example 22 from the compound synthesized in Section 78-2.
- Example 80 N - [( ⁇ 2-t ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl) amino) carbonothioyl] -4-methoxybenzamide
- Example 82 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ quinoxaline-2-carboxamide
- the organic phase is poured into ice water and then neutralized with a saturated sodium bicarbonate solution and then with a saturated solution of sodium chloride. We dry organic phase over sodium sulfate and then the solvent is evaporated on a rotary evaporator.
- the oil thus obtained is chromatographed on a Biotage silica column (eluent: dichloromethane-MeOH: 100-0 to 90-10) and a solid is obtained in the form of a pale yellow powder.
- the reaction yield is 38%.
- Example 83 4-Benzoyl-N- ⁇ 2 - [ ⁇ 2 - [(2,6-dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ benzamide
- Example 84 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -2-phenoxypropanamide
- Example 85 N- ⁇ 2 - [ ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -9-oxo-9H-fluorene-4- carboxamide R2008 / 000620
- Example 88 N- ⁇ 2-t ⁇ 2 - [(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl) amino] ethyl ⁇ (methyl) amino] ethyl ⁇ -3- (trifluoromethyl) benzenesulfonamide
- the phosphatase activity of the MBP-Cdc25C protein is assessed by the dephosphorylation of 3-O-methylfluorescein-phosphate (OMFP) to 3-O-methylfluorescein (OMF) with a determination of the fluorescence at 475 nm of the reaction product. This test makes it possible to identify inhibitors of the recombinant Cdc25 enzyme.
- OMFP 3-O-methylfluorescein-phosphate
- OMF 3-O-methylfluorescein
- the reaction is carried out in 384-well plate format in a final volume of 50 ⁇ l.
- the MBP-Cdc25C protein (prepared as described above) is stored in the following elution buffer: 20 mM Tris-HCl pH 7.4; 250 mM NaCl; ImM EDTA; 1mM dithiothreitol (DTT); 10 mM maltose. It is diluted to the concentration of 60 ⁇ M in the next reaction buffer: 50 mM Tris-HCl pH 8.2; 50 mM NaCl; 1 mM DTT; 20% glycerol.
- the measurement of the background noise is carried out with the buffer without the addition of the enzyme. The products are tested at decreasing concentrations starting from 40 ⁇ M.
- the reaction is initiated by the addition of a final 500 ⁇ M OMFP solution (prepared extemporaneously from a 12.5 mM stock solution in 100% DMSO (Sigma # M2629)). After 4 hours at 30 ° C. in a 384-well single-use plate, the fluorescence measured at OD 475 nm is read using a Victor 2 plate reader (EGG-Wallac). Determination of the concentration inhibiting the enzymatic reaction by 50% is calculated from three independent experiments. Only the values contained in the linear part of the sigmoid are retained for the linear regression analysis.
- modified Dulbecco's Eagle medium Gibco-Brl, Cergy-Pontoise, France
- the cells were treated on day 1 for 96 hours with increasing concentrations of each of the test compounds up to 10 ⁇ M. At the end of this period, quantification of cell proliferation is evaluated by colorimetric assay based on the cleavage of the tetrazolium salt WST1 by mitochondrial dehydrogenases in viable cells leading to the formation of formazan (Boehringer Mannheim, Meylan, France ). These tests are performed in duplicate with 8 determinations per concentration tested. For each test compound, the values included in the linear part of the sigmoid were retained for a linear regression analysis and used to estimate the IC 50 inhibitory concentration. The products are solubilized in dimethylsulfoxide (DMSO) at 10 -2 M and used in culture with 0.1% DMSO final. Test results:
- DMSO dimethylsulfoxide
- the compounds of Examples 1 to 56, 58 to 62, 64, 66, 67, 69, 71, 73, 75 to 77, 80, 81, and 83 to 89 have an IC 50 less than or equal to 10,000 nM on the activity. of the purified Cdc25-C recombinant enzyme.
- Examples 1 to 24, 26 to 56, 58 to 62, 64, 67, 69, 71, 73, 77, 80, 81, and 83-89 have an IC 50 less than or equal to 5000 nM.
- Examples 7, 10, 13 to 17, 19, 22, 26, 28, 38 to 40, 43, 44, 46, 47, 49 to 53, 59 to 62, 67, 69, 71, 77, 81, and 87 have an IC 50 less than or equal to 1000 nM.
- the compounds of Examples 7, 10, 11, 15 to 17, 19 to 27, 29, 30, 33 to 49, 51 to 58, 60, 62, 64, 67, 69, 71, 73, 75 to 77, 79, and 84 to 89 have an IC 50 less than or equal to 5000 nM on the cell proliferation of Mia-Paca2 lines.
- Examples 7, 10, 11, 20, 22 to 25, 30, 33 to 37, 39 to 41, 43 to 45, 49, 51, 52, 54 to 58, 67, 69, 71, and 77 have an IC 50 less than or equal to 1000 nM.
- Compounds of Examples 7, 10, 11, 15 to 17, 19 to 25, 27; 29, 30, 33 to 49, 51 to 58, 60, 62, 67, 69, 71, 73, 75 to 77, 88, and 89 have an IC 50 of less than or equal to 5000 nM on the cell proliferation of 145.
- Examples 7, 20, 22, 34, 39 to 41, 43, 49, 52, 54 to 58, 67, 71, and 77 have an IC 50 of less than or equal to 1000 nM.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010504793A JP2010526045A (ja) | 2007-05-04 | 2008-04-30 | Cdc25ホスファターゼインヒビターとしてのトリアミノピリミジン誘導体 |
MX2009011474A MX2009011474A (es) | 2007-05-04 | 2008-04-30 | Derivados de tri-amino-pirimidina como inhibidores de fosfatasa cdc25. |
BRPI0810871-4A2A BRPI0810871A2 (pt) | 2007-05-04 | 2008-04-30 | Composto, processo de preparação de um composto, composição farmacêutica e utilização de um composto. |
CN200880014571A CN101687816A (zh) | 2007-05-04 | 2008-04-30 | 作为cdc25磷酸酶抑制剂的三氨基嘧啶衍生物 |
US12/598,842 US20100137275A1 (en) | 2007-05-04 | 2008-04-30 | Triaminopyrimidine derivatives as inhibitors of cdc25 phosphatase |
EP08805532A EP2152675A1 (fr) | 2007-05-04 | 2008-04-30 | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 |
CA002685402A CA2685402A1 (fr) | 2007-05-04 | 2008-04-30 | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 |
AU2008263805A AU2008263805A1 (en) | 2007-05-04 | 2008-04-30 | Triaminopyrimidine derivatives as inhibitors of Cdc25 phosphatase |
IL201378A IL201378A0 (en) | 2007-05-04 | 2009-10-11 | Triaminopyrimidine derivatives as inhibitors of cdc25 phosphatase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0703233 | 2007-05-04 | ||
FR0703233A FR2915747B1 (fr) | 2007-05-04 | 2007-05-04 | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008152223A1 true WO2008152223A1 (fr) | 2008-12-18 |
Family
ID=38980632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2008/000620 WO2008152223A1 (fr) | 2007-05-04 | 2008-04-30 | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20100137275A1 (fr) |
EP (1) | EP2152675A1 (fr) |
JP (1) | JP2010526045A (fr) |
KR (1) | KR20100017598A (fr) |
CN (1) | CN101687816A (fr) |
AU (1) | AU2008263805A1 (fr) |
BR (1) | BRPI0810871A2 (fr) |
CA (1) | CA2685402A1 (fr) |
FR (1) | FR2915747B1 (fr) |
IL (1) | IL201378A0 (fr) |
MX (1) | MX2009011474A (fr) |
RU (1) | RU2009144983A (fr) |
WO (1) | WO2008152223A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2945532A1 (fr) * | 2009-05-15 | 2010-11-19 | Ipsen Pharma Sas | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2918665B1 (fr) * | 2007-07-13 | 2009-10-02 | Sod Conseils Rech Applic | Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25 |
FR2945530A1 (fr) * | 2009-05-15 | 2010-11-19 | Ipsen Pharma Sas | Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25 |
WO2010130900A2 (fr) * | 2009-05-15 | 2010-11-18 | Ipsen Pharma S.A.S. | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996026941A1 (fr) * | 1995-03-02 | 1996-09-06 | Pharmacia & Upjohn Company | PYRIMIDO[4,5-b]INDOLES |
WO2002009686A2 (fr) * | 2000-07-28 | 2002-02-07 | Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) | Inhibiteurs de phosphatases cdc25 |
FR2879598A1 (fr) * | 2004-12-17 | 2006-06-23 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
US20060281712A1 (en) * | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0263213B1 (fr) * | 1986-10-09 | 1995-09-06 | The Upjohn Company | Stéroides aminés en C20 à C26 |
FR2677884B1 (fr) * | 1991-06-20 | 1993-07-09 | Oreal | Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues. |
AU9649698A (en) * | 1997-10-29 | 1999-05-17 | Taisho Pharmaceutical Co., Ltd. | Erythromycin a 11, 12-carbamate derivatives |
EP1672392B1 (fr) * | 2004-12-17 | 2009-10-28 | Services Petroliers Schlumberger | Méthode pour déterminer la saturation en eau d'une formation souterraine |
GB0503962D0 (en) * | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
-
2007
- 2007-05-04 FR FR0703233A patent/FR2915747B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-30 CN CN200880014571A patent/CN101687816A/zh active Pending
- 2008-04-30 KR KR1020097025250A patent/KR20100017598A/ko not_active Application Discontinuation
- 2008-04-30 CA CA002685402A patent/CA2685402A1/fr not_active Abandoned
- 2008-04-30 BR BRPI0810871-4A2A patent/BRPI0810871A2/pt not_active IP Right Cessation
- 2008-04-30 RU RU2009144983/04A patent/RU2009144983A/ru not_active Application Discontinuation
- 2008-04-30 MX MX2009011474A patent/MX2009011474A/es active IP Right Grant
- 2008-04-30 AU AU2008263805A patent/AU2008263805A1/en not_active Abandoned
- 2008-04-30 US US12/598,842 patent/US20100137275A1/en not_active Abandoned
- 2008-04-30 WO PCT/FR2008/000620 patent/WO2008152223A1/fr active Application Filing
- 2008-04-30 EP EP08805532A patent/EP2152675A1/fr not_active Withdrawn
- 2008-04-30 JP JP2010504793A patent/JP2010526045A/ja active Pending
-
2009
- 2009-10-11 IL IL201378A patent/IL201378A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996026941A1 (fr) * | 1995-03-02 | 1996-09-06 | Pharmacia & Upjohn Company | PYRIMIDO[4,5-b]INDOLES |
WO2002009686A2 (fr) * | 2000-07-28 | 2002-02-07 | Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) | Inhibiteurs de phosphatases cdc25 |
FR2879598A1 (fr) * | 2004-12-17 | 2006-06-23 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
US20060281712A1 (en) * | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
Non-Patent Citations (4)
Title |
---|
CAO S ET AL: "Sesterterpenoids and an alkaloid from a Thorectandra sp. as inhibitors of the phosphatase Cdc25B", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 13, no. 17, 1 September 2005 (2005-09-01), pages 5094 - 5098, XP004992839, ISSN: 0968-0896 * |
CONTOUR-GALCERA ET AL: "What's new on CDC25 phosphatase inhibitors", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 115, no. 1, July 2007 (2007-07-01), pages 1 - 12, XP022134150, ISSN: 0163-7258 * |
ECKSTEIN ET AL: "Cdc25 as a potential target of anticancer agents", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 18, 2000, pages 149 - 156, XP002340121, ISSN: 0167-6997 * |
KRISTJANSDOTTIR ET AL: "Cdc25 Phospatases and cancer", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 11, August 2004 (2004-08-01), pages 1043 - 1051, XP002340122, ISSN: 1074-5521 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2945532A1 (fr) * | 2009-05-15 | 2010-11-19 | Ipsen Pharma Sas | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 |
Also Published As
Publication number | Publication date |
---|---|
CN101687816A (zh) | 2010-03-31 |
MX2009011474A (es) | 2009-11-10 |
JP2010526045A (ja) | 2010-07-29 |
EP2152675A1 (fr) | 2010-02-17 |
US20100137275A1 (en) | 2010-06-03 |
FR2915747A1 (fr) | 2008-11-07 |
IL201378A0 (en) | 2010-05-31 |
AU2008263805A1 (en) | 2008-12-18 |
FR2915747B1 (fr) | 2011-02-25 |
KR20100017598A (ko) | 2010-02-16 |
BRPI0810871A2 (pt) | 2014-10-29 |
CA2685402A1 (fr) | 2008-12-18 |
RU2009144983A (ru) | 2011-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100837420B1 (ko) | 5-히드록시-인돌-3-카르복시산에스테르 유도체 및 이의용도 | |
EP2024335B1 (fr) | Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament | |
JP2006527210A (ja) | ホルモン感受性リパーゼ阻害剤としてのピリジニルカルバメート | |
CZ292942B6 (cs) | Derivát (N-hydroxykarbamoyl)-1-(4-fenoxy)benzensulfonylu | |
WO1993014070A2 (fr) | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques | |
FR2569694A1 (fr) | Derives d'ethylenediaminemonoamide, composition pharmaceutique les contenant et utilisation de ces composes a titre d'antidepresseur ou d'antiparkinsonien | |
KR20120120956A (ko) | 알킬아민 유도체 | |
JP6434528B2 (ja) | 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 | |
EP0520883B1 (fr) | Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique | |
WO2008152223A1 (fr) | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 | |
CA2527192C (fr) | Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament | |
JP3410476B2 (ja) | 新規なエポキシコハク酸アミド誘導体又はその塩 | |
JP2003505367A (ja) | マトリックスメタロプロテイナーゼ阻害剤としての3−アリールスルホニル−2−(置換メチル)プロパン酸誘導体 | |
EP2178848A1 (fr) | Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25 | |
JP2006527211A (ja) | ホルモン感受性リパーゼの阻害剤として使用するための1−アリール−4−(アリールオキシカルボニル)−ピペラジン誘導体 | |
FR2877667A1 (fr) | Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques | |
EP3891155B1 (fr) | Dérivés de 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide pour l'induction de la chondrogenèse pour le traitement des lésions articulaires | |
US20020187987A1 (en) | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | |
FR2945530A1 (fr) | Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25 | |
KR100551944B1 (ko) | 신규에폭시숙신아미드유도체또는그의염 | |
WO2010130900A2 (fr) | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 | |
FR2945532A1 (fr) | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 | |
FR2832152A1 (fr) | Utilisation de derives de 2-amino-thiazoline comme inhibiteurs de no-synthase inductible |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880014571.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08805532 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201378 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6538/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/011474 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2685402 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010504793 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12598842 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008263805 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008805532 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008263805 Country of ref document: AU Date of ref document: 20080430 Kind code of ref document: A Ref document number: 20097025250 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009144983 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0810871 Country of ref document: BR Kind code of ref document: A2 Effective date: 20091028 |